Atsuhiko Sakamoto

Dr. Atsuhiko Sakamoto

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
ISIwao Sugitani
Iwao Sugitani
KTKazuhisa Toda
Kazuhisa Toda
NYNoriko Yamamoto
Noriko Yamamoto
ASAtsuhiko Sakamoto
Atsuhiko Sakamoto
YFYoshihide Fujimoto
Yoshihide Fujimoto

12 December 2023 in Heliyon
Verified
Journal Article
Open access
MYMichinobu Yoshimura Yoshimura
Michinobu Yoshimura Yoshimura
ASAtsuhiko Sakamoto
Atsuhiko Sakamoto
RORyo Ozuru
Ryo Ozuru
YKYusuke Kurihara
Yusuke Kurihara
RIRyota Itoh
Ryota Itoh
KHKenji Hiromatsu
Kenji Hiromatsu
This study aims to examine whether the parenterally administered mRNA-based COVID-19 vaccines can induce sufficient mucosal-type IgA responses to prevent SARS-CoV-2 transmission. We examined the longitudinal kinetics of SARS-CoV-2 spike RBD-specific IgA and IgG responses in sera of Japanese healthcare workers (HCWs) after receiving two doses and the third dose of BNT162b2 mRNA vaccines. During the prospective cohort study, Omicron breakthrough infections occurred in 62 participants among 370 HCWs who had received triple doses of the vaccine. Pre-breakthrough sera of infected HCWs and non-infected HCWs were examined for the levels of anti-RBD IgA and IgG titers. The seropositivity of anti-RBD IgA at 1 M after the second vaccine (2D-1M) and after the third dose (3D-1M) was 65.4% and 87.4%, respectively, and wanes quickly. The boosting effect on anti-RBD Ab titers following breakthrough infections was more notable for anti-RBD IgA than for IgG. There were partial cause-relationships between the lower anti-RBD IgA or IgG at pre-breakthrough sera and the breakthrough infection. Parenterally administered COVID-19 vaccines do not generate sufficient mucosal-type IgA responses despite strong systemic IgG responses to SARS-CoV-2. These results demonstrate the necessity and importance of reevaluating vaccine design and scheduling to efficiently increase oral or respiratory mucosal immunity against SARS-CoV-2.

29 September 2025 in Cells
Verified
Journal Article
Open access
PDF file
BCBin Chou
Bin Chou
KIKazunari Ishii
Kazunari Ishii
YKYusuke Kurihara
Yusuke Kurihara
ASAkinori Shimizu
Akinori Shimizu
MYMichinobu Yoshimura Yoshimura
Michinobu Yoshimura Yoshimura
KHKenji Hiromatsu
Kenji Hiromatsu
Neutrophils are among the first cells to be recruited to the lungs during Chlamydia pneumoniae infection in mouse models; however, their regulatory functions are not yet fully understood. This study examined the mechanisms and significance of IL-10-producing neutrophils throughout C. pneumoniae pulmonary infection in C57BL/6 mice. Our findings revealed that infection with C. pneumoniae induces IL-10 secretion in bone marrow-derived neutrophils, depending on Toll-like receptor 2 (TLR2) activation. This process involves TLR2-dependent mitochondrial reactive oxygen species (ROS) production, which triggers the endoplasmic reticulum (ER) stress pathway, including IRE1α and subsequent Xbp1 splicing. Inhibition of this pathway or depletion of neutrophils (using the 1A8 monoclonal antibody) significantly reduces IL-10 levels in bronchoalveolar lavage fluid (BALF) in vivo. Conversely, the absence of IL-10-producing neutrophils, whether through depletion or TLR2 deficiency, leads to increased IL-12p70 and IFN-γ-positive NK cells, along with decreased regulatory T cells and M2-like macrophages. This results in a lower bacterial burden in the lungs but causes more severe pulmonary damage and decreased survival rates. These findings highlight that IL-10 produced by neutrophils via the TLR2-mitochondrial ROS–ER stress pathway is essential for modulating pulmonary immune responses and maintaining immune homeostasis during C. pneumoniae infection, thereby preventing excessive inflammation and tissue damage.

24 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAtsuhiko Sakamoto
Atsuhiko Sakamoto
MYMichinobu Yoshimura Yoshimura
Michinobu Yoshimura Yoshimura
RIRyota Itoh
Ryota Itoh
RORyo Ozuru
Ryo Ozuru
KIKazunari Ishii
Kazunari Ishii
KHKenji Hiromatsu
Kenji Hiromatsu
Analysis of longitudinal dynamics of humoral immune responses to the BNT162b2 COVID-19 vaccine might provide useful information to predict the effectiveness of BNT162b2 in preventing SARS-CoV-2 infection. Herein, we measure anti-RBD IgG at 1, 3 and 6 months (M) after the second dose of BNT162b2, and at 1 M after a third dose of BNT162b2 vaccination in 431 COVID-19-naïve healthcare workers (HCWs) in Japan. All HCWs mounted high-anti-RBD IgG responses after the two-dose regimen of BNT162b2 vaccinations. Older persons and males presented lower anti-RBD IgG responses than younger adults and females, respectively. The decay in anti-RBD IgG started from 1 M after the second dose of BNT162b2 and anti-RBD IgG titers dropped to nearly one-tenth at 6 M after the second vaccination. Subsequently, the participants received a third dose of BNT162b2 at 8 M after the second dose of BNT162b2 vaccine. Anti-RBD antibody titers 1 M after the third dose of BNT162b2 increased seventeen times that of 6 M after the second dose, and was twice higher than the peak antibody titers at 1 M after the second dose of vaccination. The negative effect of age for the male gender on anti-RBD IgG antibody titers was not observed at 1 M after the third dose of BNT162b2 vaccine. There were no notable adverse events reported, which required hospitalization in these participants. These results suggest that the third dose of BNT162b2 safely improves humoral immunity against SARS-CoV-2 with no major adverse events.

15 November 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
KIKazunari Ishii
Kazunari Ishii
TSToshinori Soejima
Toshinori Soejima
YOYoshiki Ohnishi
Yoshiki Ohnishi
RORyo Ozuru
Ryo Ozuru
RIRyota Itoh
Ryota Itoh
KHKenji Hiromatsu
Kenji Hiromatsu
Chlamydia trachomatis infection causes pelvic inflammatory disease and infertility, but how host immune factors control pathogen clearance or pathology is not fully understood. Using a mouse model of genital tract infection with Chlamydia muridarum, we examined the role of CD1d-restricted Natural killer T (NKT) cells. Invariant NKT cell-deficient mice (Jα18−/−) showed prolonged vaginal shedding of infectious elementary bodies (EBs), delayed clearance, and decreased early cytokine production compared to wild-type (WT) controls. Conversely, CD1d−/− mice, which lack both invariant and diverse NKT cells, did not show significant differences in vaginal shedding compared to WT mice. Surprisingly, both NKT-deficient mice (Jα18−/− and CD1d−/−) produced higher levels of inflammatory cytokines in the oviduct at day 35 post-infection (p.i.) and experienced more frequent upper genital tract pathology (hydrosalpinx) at day 80 p.i. However, no infectious EBs were recovered from the oviducts or uterine horns of NKT-deficient mice after day 35 p.i. Cortisone acetate reactivated infectious shedding in chronically infected NKT-deficient mice at day 100 p.i. These findings highlight distinct roles for NKT cell subsets: invariant NKT cells promote early clearance via rapid cytokine production, while the broader NKT population helps limit tissue damage. Targeting NKT pathways could help prevent chronic infection and infertility.

1 November 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
HOHiroki Ota
Hiroki Ota
TOTomohiro Ota
Tomohiro Ota
YTYoko Tsukumo
Yoko Tsukumo
ASAtsuhiko Sakamoto
Atsuhiko Sakamoto
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.